Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Gets Advisory Committee Support For Firazyr Self-Administration Claim

Executive Summary

Shire will enter discussions with FDA on labeling for its hereditary angioedema drug Firazyr (icatibant) with backing from an advisory panel for a claim to allow patients to self-administer the product, which is delivered through subcutaneous injection.

You may also be interested in...

FDA Relies On Experience To Judge Firazyr Self-Administration

The Center for Devices and Radiological Health recommended a delay in approving Firazyr until a human factors study could be conducted to rule out risks associated with the self-administration device, but CDER reviewers concluded that experience with the device in clinical trials and real life was sufficient to demonstrate safety.

FDA Asks If PRO Used For Shire's Firazyr Is Clinically Meaningful

FDA finds no faults with self-administration for the hereditary angioedema drug as it takes the new molecular entity to a June 23 advisory panel.

Jerini’s Icatibant Falters in U.S., Wins In Europe

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts